Bicycle Therapeutics Sets 2026 Oncology and Radiopharma Priorities

Bicycle Therapeutics ( (BCYC) ) has issued an update.

On January 12, 2026, Bicycle Therapeutics outlined its 2025 achievements and strategic priorities for 2026, emphasizing clinical progress in its oncology pipeline and expansion of its radiopharmaceutical capabilities. During 2025 the company advanced zelenectide pevedotin through updated Phase 1 Duravelo-1 data in metastatic urothelial cancer, initiated the Phase 1/2 Duravelo-3 and Duravelo-4 trials in NECTIN4-amplified breast and non-small cell lung cancers, and presented initial human imaging results for its EphA2- and MT1-MMP-targeting radioconjugates, reinforcing the therapeutic potential of these targets and its BRC platform. For 2026, Bicycle plans a series of clinical and data milestones, including dose selection and an update on the potential approval pathway for zelenectide pevedotin from the Phase 2/3 Duravelo-2 pivotal trial in metastatic urothelial cancer in the first quarter, multiple additional readouts across its Nectin-4 and EphA2 programs over the year, and further human imaging data for EphA2, all supported by an expected cash runway into 2028 that underpins execution of its clinical and strategic agenda.

The most recent analyst rating on (BCYC) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.

Spark’s Take on BCYC Stock

According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.

Bicycle Therapeutics’ overall stock score is primarily impacted by its financial performance, which is challenged by negative margins and cash flow issues. The technical analysis suggests neutral momentum, while the valuation reflects the company’s unprofitability. The positive corporate event of board expansion provides some strategic optimism.

To see Spark’s full report on BCYC stock, click here.

More about Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage pharmaceutical company developing a novel class of fully synthetic bicyclic peptide medicines, known as Bicycle molecules, for diseases underserved by existing therapies, with a primary focus on oncology. Its pipeline includes zelenectide pevedotin, a Bicycle Drug Conjugate targeting the tumor antigen Nectin-4; BT5528, a Bicycle Drug Conjugate targeting the historically hard-to-drug EphA2; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137, alongside a growing portfolio of Bicycle Radioconjugates for radiopharmaceutical applications developed from its bases in Cambridge, UK, and Cambridge, Massachusetts.

Average Trading Volume: 299,121

Technical Sentiment Signal: Sell

Current Market Cap: $459.5M

For detailed information about BCYC stock, go to TipRanks’ Stock Analysis page.